GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab
16 Novembre 2022 - 3:00PM
Business Wire
- Expression of the pathogenic W-ENV protein triggered by the
SARS-CoV-2 infection, continuing long after the acute phase has
been resolved, is suspected to have a major role in the persistence
of inflammation in many long-COVID patients.
- The personalized medicine trial will evaluate temelimab, the
anti-W-ENV antibody developed by GeNeuro, as a Disease Modifying
Therapy in long-COVID patients and who are positive for the
presence of the pathogenic W-ENV protein in their blood,
representing more than one in four patients in analyzed long-COVID
patient cohorts.
- Long-COVID has become a major public-health concern worldwide,
affecting millions of individuals. While most patients recover over
time, there is a part of the population whose symptoms remain
severe and are deeply affected in their quality of life and ability
to work.
Access here the complete Press release
GeNeuro (Paris:GNRO)(Euronext Paris: CH0308403085 - GNRO), a
biopharmaceutical company focused on stopping causal factors
driving the progression of neurodegenerative and autoimmune
diseases such as multiple sclerosis (MS), amyotrophic lateral
sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC,
long-COVID or post-COVID), today announced the recruitment of first
patients in its Phase 2 trial evaluating temelimab against
long-COVID at the Geneva University Hospitals post-COVID clinic
(lead centre), as well as in all the other Swiss clinical centres
participating to the study, i.e., Inselspital in Bern, REHAB Basel,
Kantonsspital Graubünden in Chur and the Centre Hospitalier du
Valais Romand in Sion (for more information, please refer to
clinical trials.gov or to GeNeuro’s web site).
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments
against neurological disorders and autoimmune diseases, such as
multiple sclerosis, by neutralizing causal factors encoded by human
endogenous retroviruses (HERVs), which represent 8% of human
DNA.
GeNeuro is based in Geneva, Switzerland and has R&D
facilities in Lyon, France. It has rights to 17 patent families
protecting its technology.
For more information, visit: www.geneuro.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221116005201/en/
GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552 4800
investors@geneuro.com NewCap (France) Mathilde Bohin/ Louis-Victor
Delouvrier (investors) +33 1 44 71 98 52 Arthur Rouillé (media) +33
1 44 71 94 98 geneuro@newcap.eu RooneyPartners (US) Jeanene
Timberlake (media) +1 646 770 8858
jtimberlake@rooneypartners.com
Grafico Azioni GeNeuro (EU:GNRO)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni GeNeuro (EU:GNRO)
Storico
Da Apr 2023 a Apr 2024